Search

WALL STREET PAYDAY: 4 banks made a killing from Monday's $20 billion in biotech deals

WALL STREET PAYDAY: 4 BANKS MADE A KILLING FROM MONDAY'S $20 BILLION IN BIOTECH DEALS

Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia...

Two drug companies are exploding after a pair of biotech mega-deals

TWO DRUG COMPANIES ARE EXPLODING AFTER A PAIR OF BIOTECH MEGA-DEALS

Markets Insider French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno...

 
 
 
Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion

CELGENE IS BUYING CANCER DRUGMAKER JUNO THERAPEUTICS FOR $9 BILLION

Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion. It's the second...

 
 
 

CELGENE SCOOPS UP SAN DIEGO BIOTECH IN $7B DEAL

The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.

J.P. MORGAN KICKS OFF WITH A DEAL AS CELGENE PAYS $1.1B FOR IMPACT BIOMEDICINES

On the first day of the big biotech conference that is J.P. Morgan, Celgene has come right out on day one with M&A news.

 
 
 

AFTER 2ND BET ON FAMILIAR DRUG, IMPACT BIO LANDS $1B CELGENE BUYOUT

Celgene has kicked off J.P. Morgan week-the annual healthcare investment gathering in San Francisco-with a blockbuster deal, acquiring...

DEVELOPING A SANOFI CAST-OFF, IMPACT BIOMEDICINES NOW SUBJECT OF RUMORED $7B CELGENE ACQUISITION DEAL

A startup developing the once-discarded fedratinib, a drug cast off from Sanofi due to safety concerns back in 2013, is now the subject...

 
 
 

CELGENE CO-FOUNDER BAGS $23M FOR JOHNS HOPKINS SPINOUT NEXIMMUNE

In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune's Board of Directors.

 
 
 

BLUEBIRD AND CELGENE'S CAR-T HITS THE MARK IN MYELOMA

Patients with highly advanced multiple myeloma have seen spectacular results with Bluebird Bio and Celgene's CAR-T therapy bb2121;...

ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest

IMMUSANT GETS $40M FROM ARCH, VATERA TO CONTINUE CELIAC VACCINE QUEST

ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge...

 
 
 

LONGTIME CELGENE R&D EXEC TO HELM IMMUNOMEDICS

The company also announced that Brendan Delaney has been appointed CCO, effective today.

Bio Roundup: CBO's Praise, Celgene's Shock, Trump's Opioid Plan & More

BIO ROUNDUP: CBO'S PRAISE, CELGENE'S SHOCK, TRUMP'S OPIOID PLAN & MORE

The White House and the FDA turned the spotlight on the nation's opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded...

 
 
 
Traders were blindsided by Celgene's massive earnings flop

TRADERS WERE BLINDSIDED BY CELGENE'S MASSIVE EARNINGS FLOP

Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders...

 
 
 
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More

BIO ROUNDUP: NOBEL PURSUIT, FUNDRAISING FRUIT, A RHYTHMIC IPO & MORE

The 2017 Nobel Prizes with a biomedical bent were announced this week. Three researchers shared the physiology and medicine prize for...

CELGENE CUDDLES UP WITH ANOTHER CAMBRIDGE BIOTECH, THIS TIME TO TACKLE AUTOIMMUNE DISEASES

Life Sciences Jobs ...

 
 
 
Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship's Latest Microbiome Startup

EX-CUBIST CEO BONNEY EMERGES AT KALEIDO, FLAGSHIP'S LATEST MICROBIOME STARTUP

Flagship Pioneering has been as active as any venture firm at funneling its investment dollars into microbiome drug developers. It's...